176 related articles for article (PubMed ID: 24150924)
1. Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.
Wang Y; Yu L; Xie J; Chen J; Wei Q
Asia Pac Psychiatry; 2014 Dec; 6(4):353-62. PubMed ID: 24150924
[TBL] [Abstract][Full Text] [Related]
2. New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N
Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378
[TBL] [Abstract][Full Text] [Related]
3. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis.
Sun Y; Liang Y; Jiao Y; Lin J; Qu H; Xu J; Zhao C
BMJ Open; 2017 Aug; 7(8):e016499. PubMed ID: 28775189
[TBL] [Abstract][Full Text] [Related]
5. Fluoxetine versus other types of pharmacotherapy for depression.
Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine extended-release: a review of its use in the management of major depression.
Wellington K; Perry CM
CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
[TBL] [Abstract][Full Text] [Related]
7. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
8. Clinical practice guidelines for depression in young people.
Jureidini JN; Tonkin AL
Med J Aust; 2003 Mar; 178(6):300; author reply 300-2. PubMed ID: 12633493
[No Abstract] [Full Text] [Related]
9. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
[TBL] [Abstract][Full Text] [Related]
10. Agomelatine versus other antidepressive agents for major depression.
Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
[TBL] [Abstract][Full Text] [Related]
11. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
12. Benefits and harms of pediatric antidepressant medications.
Edwards JL; Kirk KK; Midha CK
JAMA; 2007 Aug; 298(6):626-7; author reply 627. PubMed ID: 17684183
[No Abstract] [Full Text] [Related]
13. Fluoxetine versus other types of pharmacotherapy for depression.
Cipriani A; Brambilla P; Furukawa T; Geddes J; Gregis M; Hotopf M; Malvini L; Barbui C
Cochrane Database Syst Rev; 2005 Oct; (4):CD004185. PubMed ID: 16235353
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
15. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Paroxetine for Poststroke Depression: A Meta-Analysis.
Li L; Han Z; Li L; Han L; Yan B
J Stroke Cerebrovasc Dis; 2020 May; 29(5):104664. PubMed ID: 32093988
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
Judge R; Parry MG; Quail D; Jacobson JG
Int Clin Psychopharmacol; 2002 Sep; 17(5):217-25. PubMed ID: 12177584
[TBL] [Abstract][Full Text] [Related]
19. Comparative efficacy, acceptability, and safety of medicinal, cognitive-behavioral therapy, and placebo treatments for acute major depressive disorder in children and adolescents: a multiple-treatments meta-analysis.
Ma D; Zhang Z; Zhang X; Li L
Curr Med Res Opin; 2014 Jun; 30(6):971-95. PubMed ID: 24188102
[TBL] [Abstract][Full Text] [Related]
20. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
